Clinical case of benralizumab use in severe eosinophilic bronchial asthma in the Republic of Dagestan

Abstract

This article presents the results of the examination, observation, and treatment of a patient with severe persistent bronchial asthma with an eosinophilic phenotype who received benralizumab (Fazenra) in a complex treatment. Benralizumab is indicated for patients with severe bronchial asthma with an eosinophilic phenotype in adult patients as an additional maintenance therapy, in which the use of glucocorticosteroids does not achieve control over the symptoms of the disease. With complex therapy, the inclusion of benralizumab led to positive dynamics of both clinical symptoms and indicators of respiratory function, which allowed us to reduce the volume of therapy with corticosteroids and achieve disease control. The above case is of interest to both pulmonologists and therapists.